Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

A 12 Week Multi Center, Open Label, Single Arm Study to Assess the Safety and Efficacy of Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.

Inclusion Criteria:

• Patients who sign the informed consent
• HbA1c in the range of > 7 to ≤10.5% at Visit 1
• Ability to comply with all study requirements

Exclusion Criteria:

• Pregnant or lactating women
• Serious cardiovascular disorders
• Liver/renal disease or dysfunction
• Anti-diabetic other than metformin, thiazolidine, or α-GI or insulin
• Laboratories values abnormalities as defined by the protocol